Navigation Links
CareFusion Signs Multi-Year Technology Licensing Agreement for Masimo Rainbow SET(R) Pulse CO-Oximetry(TM)
Date:11/12/2009

IRVINE, Calif., Nov. 12 /PRNewswire-FirstCall/ -- Masimo (Nasdaq: MASI), the inventor of Pulse CO-Oximetry(TM) and Measure-Through Motion and Low-Perfusion pulse oximetry, and CareFusion (NYSE: CFN), a leading global medical device company, today announced a multi-year technology licensing agreement establishing the breakthrough noninvasive blood constituent monitoring capabilities of Masimo Rainbow SET Pulse CO-Oximetry technology to be used in CareFusion infusion and respiratory products under development*.

Incorporating Masimo Rainbow SET Pulse CO-Oximetry technology will enable CareFusion's future infusion and respiratory products (under development*) to noninvasively and continuously measure multiple blood constituents to more accurately assess dyshemoglobins affecting oxygenation, predict fluid responsiveness, and provide earlier identification of respiratory compromise. The ability to automatically assess total hemoglobin (SpHb(TM)), oxygen content (SpOC(TM)), carboxyhemoglobin (SpCO®), methemoglobin (SpMet®), and PVI® for fluid responsiveness, in addition to oxyhemoglobin (SpO2), perfusion index (PI), and pulse rate directly from CareFusion's ventilators and infusion pumps may facilitate earlier detection, diagnosis and treatment of potentially life-threatening conditions.

Currently, CareFusion uses Masimo technology in the Alaris® SpO2 module to help safeguard PCA delivery through the Alaris® System. The Alaris® PCA module together with the Alaris® SpO2 module--featuring Masimo SET® pulse oximetry technology for accurate and trustworthy measure-through motion and low-perfusion SpO2, pulse rate, and perfusion index measurements--provides an additional safety net for risk factors not covered by programming safety and bar coding, such as previously undiagnosed clinical conditions and PCA by proxy. The system offers the clinician the unique ability to automatically pause PCA infusion if a patient falls below hospital-defined respiratory monitoring limits.

"Masimo is a great partner with excellent technology," said Gordon LaFortune, senior vice president and general manager of Infusion Systems for CareFusion. "We're happy to be working with them to incorporate their technology in our products."

Masimo President of OEM Business, Rick Fishel stated, "We look forward to a growing technology partnership with CareFusion and the possibilities created by the integration of Masimo Rainbow SET into CareFusion's infusion and respiratory products."

*Future vision: As of the date of the communication, the products under development have not been cleared for commercial sale by the FDA. The products under development may not be cleared for commercial sale by the FDA. The company may not make the products under development available for commercial sale.

About Masimo

Masimo (Nasdaq: MASI) develops innovative monitoring technologies that significantly improve patient care--helping solve "unsolvable" problems. In 1995, the company debuted Measure-Through Motion and Low-Perfusion pulse oximetry, known as Masimo SET®, which virtually eliminated false alarms and increased pulse oximetry's ability to detect life-threatening events. More than 100 independent and objective studies demonstrate Masimo SET provides the most reliable SpO2 and pulse rate measurements even under the most challenging clinical conditions, including patient motion and low peripheral perfusion. In 2005, Masimo introduced Masimo Rainbow SET® Pulse CO-Oximetry(TM), a breakthrough noninvasive blood constituent monitoring platform that can measure many blood constituents that previously required invasive procedures. Masimo Rainbow SET continuously and noninvasively measures total hemoglobin (SpHb(TM)), oxygen content (SpOC(TM)), carboxyhemoglobin (SpCO®), methemoglobin (SpMet®), and PVI(TM), in addition to oxyhemoglobin (SpO2), pulse rate (PR), and perfusion index (PI), allowing early detection and treatment of potentially life-threatening conditions. Founded in 1989, Masimo has the mission of "Improving Patient Outcomes and Reducing Cost of Care by Taking Noninvasive Monitoring to New Sites and Applications." Additional information about Masimo and its products may be found at www.masimo.com.

Forward Looking Statements

This press release includes forward-looking statements as defined in Section 27A of the Securities Act of 1933 and Section 21E of the Securities Exchange Act of 1934, in connection with the Private Securities Litigation Reform Act of 1995. These forward-looking statements are based on current expectations about future events affecting us and are subject to risks and uncertainties, all of which are difficult to predict and many of which are beyond our control and could cause our actual results to differ materially and adversely from those expressed in our forward-looking statements as a result of various risk factors, including, but not limited to: risks related to the timing, commercial availability, and regulatory clearance of CareFusion infusion and respiratory products under development that may or may not incorporate Masimo Rainbow SET, risks related to our assumptions regarding the repeatability of clinical results, risks related to our belief that the noninvasive blood constituent monitoring capabilities of Masimo Rainbow SET may facilitate earlier detection, diagnosis, and treatment of potentially life-threatening conditions to increase patient safety, improve the quality of care, and reduce the cost of care, risks related to our belief that Masimo SET will deliver sufficient sensitivity and specificity to deliver the most accurate and reliable measurements under all conditions of patient motion and low peripheral perfusion, and risks related to our assumption that Masimo SET will help improve the regulation and delivery of oxygen therapy to neonates, as well as other factors discussed in the "Risk Factors" section of our most recent reports filed with the Securities and Exchange Commission ("SEC"), which may be obtained for free at the SEC's website at www.sec.gov. Although we believe that the expectations reflected in our forward-looking statements are reasonable, we do not know whether our expectations will prove correct. All forward-looking statements included in this press release are expressly qualified in their entirety by the foregoing cautionary statements. You are cautioned not to place undue reliance on these forward-looking statements, which speak only as of today's date. We do not undertake any obligation to update, amend or clarify these forward-looking statements or the "Risk Factors" contained in our most recent reports filed with the SEC, whether as a result of new information, future events or otherwise, except as may be required under the applicable securities laws.

    Media Contacts:
    Dana Banks
    Masimo Corporation
    +1 (949) 297-7348

Masimo, SET, Signal Extraction Technology, Improving Outcomes and Reducing Cost of Care by Taking Noninvasive Monitoring to New Sites and Applications, Rainbow, SpHb, SpOC, SpCO, SpMet, PVI, Radical-7, Rad-87, Rad-57,Rad-9, Rad-8, Rad-5,Pulse CO-Oximetry and Pulse CO-Oximeter are trademarks or registered trademarks of Masimo Corporation.

SOURCE Masimo


'/>"/>
SOURCE Masimo
Copyright©2009 PR Newswire.
All rights reserved

Related medicine technology :

1. CareFusion Earns Top Ranking in MD Buyline and KLAS Reports
2. CareFusion Will Host An Earnings Conference Call on November 10, 2009 to Discuss the Results for the First Quarter of Fiscal 2010
3. CareFusion Shipping Ventilators to CDC for National Emergency Preparedness
4. CareFusion Moves First Quarter Earnings Announcement to November 5
5. CareFusion Reports First Quarter Results, Raises Full-Year Outlook
6. Quark Pharmaceuticals Signs Collaboration Agreement With University of Michigan for Development of Proprietary SiRNA Compounds for Noise-Induced Hearing Loss
7. StatSure Signs Strategic Financing and License Deals with Inverness Medical Innovations
8. CIMZIA(R) (certolizumab pegol), Significantly Reduces Structural Damage and Rheumatoid Arthritis Signs & Symptoms for Up to One Year
9. New Anti-TNF Golimumab Significantly Reduced Signs and Symptoms of Ankylosing Spondylitis According to Phase 3 Study Findings
10. New AVEENO(R) Eczema Care Product Line Offers Breakthrough Formulas to Help Manage the Signs and Symptoms of Eczema
11. ALS Therapy Development Institute Signs Collaboration Agreement with the Allen Institute for Brain Science
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:2/9/2016)... Feb. 9, 2016 The new report "Global Blood Monitoring & Cardiac ... Research & Consulting group reveals that global market for blood monitoring ... 2014 and expected to grow to US$ 24,830.1 million by 2019 ... North America , Europe , ... Middle-East and Africa . The ...
(Date:2/9/2016)... Feb. 9, 2016  Increasingly, health care professionals are ... signs with wireless technology. With the Vios Monitoring System ... oversight and remotely detect problems before they become serious ... in-hospital environments. the United States ... . --> The Vios Monitoring ...
(Date:2/9/2016)... 2016  Johnson & Johnson (NYSE: JNJ ) ... Conference on Tuesday, Feb. 23, at the New York ... Vice President, Finance & Chief Financial Officer and ... Company in a session scheduled at 10:00 a.m. (Eastern ... www.investor.jnj.com . --> This webcast will be ...
Breaking Medicine Technology:
(Date:2/8/2016)... ... February 08, 2016 , ... The ... website, federallabs.org . The site houses a wealth of federal resources that ... through the process called technology transfer (T2). As a network of over 300 ...
(Date:2/8/2016)... ... February 08, 2016 , ... Coast Dental has a new ... Children’s Dental Health Month and family dentist Yvonne Dorrian, DMD, is hosting a free ... Dental , located next to Target at 1207 North Peachtree Parkway in Peachtree City. ...
(Date:2/8/2016)... Dallas, Texas (PRWEB) , ... February 08, 2016 , ... The Valentine’s Season is famous ... family members and significant others that they are loved. This year, for more than ... much they cost - just won't be enough to remind them of the lives they’ve ...
(Date:2/8/2016)... ... February 08, 2016 , ... Brenton Engineering , ... bags, and flow wrapped products at WestPack 2015, February 9-11, in Anaheim, California. ... up to semi-automatic or fully-automatic case packing with a small footprint, rugged, highly ...
(Date:2/8/2016)... ... February 08, 2016 , ... ... clothing, announced expansion into Canada to provide its range of unique and ... office in Quebec City that will provide bilingual customer service and marketing support. ...
Breaking Medicine News(10 mins):